NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Have you considered the likelihood of DCVax trial patients enrolling in the TOCA rGBM trial upon progression? (AVII77)

Yes, and i believe : zero chance.

You are talking about an investigational medicinal product. Only approved treatments were allowed after tumor progression/recurrence.(for patients in the DCvax-L trial.)
See:

"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma".
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6

All patients were allowed to receive DCVax-L following tumor progression/recurrence, as well as other approved treatments per local practice.

We know that the Company has treated a substantial number of patients on a compassionate basis under an Expanded Access Protocol. I assume that some of them could get an investigational medicinal product after tumor progression/recurrence.